Latest Chelsea Therapeutics International (CHTP) Headlines
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:25PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2013.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
10.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Fri Mar 07, 10:04AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 2 months, Chelsea Therapeutics International has returned 10.93% as of today's recent price of $5.58.
Chelsea Therapeutics International Shares Up 14.3% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Feb 28, 9:26AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 1 month, Chelsea Therapeutics International has returned 14.32% as of today's recent price of $5.75.
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:00AM CST
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:25AM CST
Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way. Breaking news about a big acquisition propelled one of our humongous...
Chelsea Therapeutics International Ltd: FDA Approval Just the First Hurdle
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 5:30PM CST
Chelsea's Northera, a blood pressure boosting treatment designed to help prevent fainting, finally got the FDA's go-ahead after taking shareholders on a roller coaster ride over the past few years that included a perilous fall in 2012 and an...
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Company news for February 20, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 9:06AM CST
Companies in the News are: LZB,CHTP,NBR,CF
3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...
CHTP's Northera Gains FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:20PM CST
Chelsea Therapeutics gained accelerated approval from the FDA for Northera for the treatment of symptomatic neurogenic orthostatic hypotension
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Chelsea Therapeutics International Set to Possibly Pullback After Yesterday's Rally of 24.44%
Comtex SmarTrend(R) - Wed Feb 19, 4:27PM CST
Chelsea Therapeutics International (NASDAQ:CHTP) traded in a range yesterday that spanned from a low of $5.95 to a high of $6.83. Yesterday, the shares gained 24.4%, which took the trading range above the 3-day high of $5.63 on volume of 44.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Zale, Chelsea Therapeutics, and Nabors Industries Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 19, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Today marked the second straight day of abysmal housing data,...
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:25PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2013.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
10.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Fri Mar 07, 10:04AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 2 months, Chelsea Therapeutics International has returned 10.93% as of today's recent price of $5.58.
Chelsea Therapeutics International Shares Up 14.3% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Feb 28, 9:26AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 1 month, Chelsea Therapeutics International has returned 14.32% as of today's recent price of $5.75.
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:00AM CST
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:25AM CST
Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way. Breaking news about a big acquisition propelled one of our humongous...
Chelsea Therapeutics International Ltd: FDA Approval Just the First Hurdle
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 5:30PM CST
Chelsea's Northera, a blood pressure boosting treatment designed to help prevent fainting, finally got the FDA's go-ahead after taking shareholders on a roller coaster ride over the past few years that included a perilous fall in 2012 and an...
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Company news for February 20, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 9:06AM CST
Companies in the News are: LZB,CHTP,NBR,CF
3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...
CHTP's Northera Gains FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:20PM CST
Chelsea Therapeutics gained accelerated approval from the FDA for Northera for the treatment of symptomatic neurogenic orthostatic hypotension
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Chelsea Therapeutics International Set to Possibly Pullback After Yesterday's Rally of 24.44%
Comtex SmarTrend(R) - Wed Feb 19, 4:27PM CST
Chelsea Therapeutics International (NASDAQ:CHTP) traded in a range yesterday that spanned from a low of $5.95 to a high of $6.83. Yesterday, the shares gained 24.4%, which took the trading range above the 3-day high of $5.63 on volume of 44.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Zale, Chelsea Therapeutics, and Nabors Industries Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 19, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Today marked the second straight day of abysmal housing data,...
